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Abstract
H5N1 highly pathogenic avian influenza virus (HPAIV) infection has been reported in poultry and humans with expanding
clade designations. Therefore, a vaccine that induces immunity against a broad spectrum of H5N1 viruses is preferable for
pandemic preparedness. We established a second H5N1 vaccine candidate, A/duck/Hokkaido/Vac-3/2007 (Vac-3), in our
virus library and examined the efficacy of inactivated whole particles of this strain against two clades of H5N1 HPAIV strains
that caused severe morbidity in cynomolgus macaques. Virus propagation in vaccinated macaques infected with either of
the H5N1 HPAIV strains was prevented compared with that in unvaccinated macaques. This vaccine also prevented
propagation of a pandemic (H1N1) 2009 virus in macaques. In the vaccinated macaques, neutralization activity, which was
mainly shown by anti-hemagglutinin antibody, against H5N1 HPAIVs in plasma was detected, but that against H1N1 virus
was not detected. However, neuraminidase inhibition activity in plasma and T-lymphocyte responses in lymph nodes
against H1N1 virus were detected. Therefore, cross-clade and heterosubtypic protective immunity in macaques consisted of
humoral and cellular immunity induced by vaccination with Vac-3.
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Introduction
H5N1 highly pathogenic avian influenza virus (HPAIV)
infection in humans has been reported since 1997 (http://www.
who.int/influenza/human_animal_interface/
H5N1_cumulative_table_archives/en/). Although H5N1 HPAIVs
did not appear to transmit easily among humans (http://www.
who.int/influenza/human_animal_interface/
Influenza_Summary_IRA_HA_interface_04Jun13.pdf), the public
health risks associated with H5N1 HPAIVs remain unchanged
since most humans do not possess immunity against H5N1 virus
and H5N1 HPAIVs have been detected in poultry and swine [1,2],
of which the latter is thought to be an origin of past pandemic
virus [3–5]. Therefore, development of vaccines against H5N1
HPAIVs has been required.
Mutation rates in hemagglutinin (HA) genes of avian and swine
influenza viruses were lower than those in HA genes of human
seasonal influenza viruses [1,6]. However, H5N1 HPAIVs have
genetically been divided into several clades according to HA
sequences, and further evolution of the virus has led to the
appearance of new clades and subclades as of 2012 [7,8].
Therefore, it is thought that vaccine strains should be renewed
according to circulating strains, and the development of a vaccine
that is effective against a broad spectrum of different clades is
required [9].
We have established a vaccine library containing 144 different
subtypes of non- or low pathogenic influenza viruses with
combinations of 16 hemagglutinins (HA) and 9 neuraminidases
(NA) [10]. We previously selected vaccine candidate strains from
the library to examine their efficacy against H5N1, H7N7, and
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H1N1 virus infections in cynomolgus macaques [11–13]. To
update vaccine candidates, we developed a second strain of H5N1
subtype low pathogenic reassortant influenza virus, A/duck/
Hokkaido/Vac-3/2007 (Vac-3) [14]. The Vac-3 virus propagated
more vigorously in embryonated eggs than did Vac-1, which was
the first non-pathogenic H5N1 virus in the virus library [11].
Therefore, if Vac-3 induced protective immunity against H5N1
HPAIVs, it would be a suitable vaccine candidate for vaccine
production to reduce the number of embryonated eggs required
and to produce vaccines more rapidly at pandemics [15].
In the present study, immunogenicity of the Vac-3 vaccine and
its protective efficacy against two H5N1 HPAIVs in different
clades in macaques were analyzed. Whole virus particles of Vac-3
inactivated by formalin were subcutaneously inoculated into
macaques. Neutralization activity of plasma against the vaccine
strain was detected in all macaques. In challenge infections,
duration of virus detection in vaccinated macaques infected with
the two different clades of H5N1 HPAIVs was shorter than that of
virus detection in unvaccinated macaques. Furthermore, propa-
gation of a pandemic (H1N1) 2009 virus in macaques vaccinated
with Vac-3 was prevented. The protection of vaccinated macaques
from H5N1 HPAIV and pandemic (H1N1) 2009 virus infection
was due to antibody responses against HA and NA and to T
lymphocyte responses against viral antigens. Thus, the whole
particle vaccine of Vac-3 induced immune responses against
multiple clades and subtypes.
Results
Pathogenicity of Two H5N1 Highly Pathogenic Avian
Influenza Virus Strains in Cynomolgus Macaques
Firstly, we examined the pathogenicity of highly pathogenic
avian influenza viruses, A/Vietnam/UT3040/2004 (H5N1) (clade
1, VN3040) and A/whooper swan/Hokkaido/1/2008 (H5N1)
(clade 2.3.2.1, HOK1), in cynomolgus macaques. After inocula-
tion of the virus into nasal cavities, oral cavities, and tracheas, all
macaques infected with either virus showed higher body temper-
atures over 40uC than those before infection (Figure 1). The
average of clinical scores diagnosed according to Table S4 in
macaques inoculated with HOK1 was higher than that in
macaques inoculated with VN3040 although the difference was
not statistically significant (Figure S1). One of the macaques
inoculated with HOK1, named Ho3 (abbreviations indicated in
Table S1), died 5 days after infection (survival rates on day 7 was
3/3 and 2/3 in macaques inoculated with VN3040 and HOK1,
respectively). The viruses were recovered from nasal, oral,
tracheal, and bronchial samples from macaques infected with
either strain until days 6 to 7 (Tables 1 and 2). Therefore, both
viruses propagated in upper and lower respiratory tracts of
macaques.
We examined virus titers in tissues obtained at autopsy 7 days or
5 days after infection. Virus was detected in the lungs of two and
three macaques infected with VN3040 and HOK1, respectively
(Table S2). Virus was further detected in the tonsils of all
macaques, in the jejunum of one macaque infected with VN3040
(VN2), and in samples of the brain and muscle in a dead macaque
infected with HOK1 (Ho3). Therefore, these two H5N1 strains
propagated not only in upper and lower respiratory tracts but also
in non-respiratory organs of macaques.
Histological changes in lungs of macaques infected with
VN3040 and HOK1 were assessed. Capacity for air exchange
was reduced in alveoli of macaques 7 and 5 days after infection
with VN3040 and HOK1 (Figure 2A–C). Alveolar septa were
thickened with inflammatory cells and fibrinous exudate, accom-
panied by infiltration of predominantly lymphocytes in the alveoli
(Figure 2D–F). These pathological results suggested impaired
respiratory function in the macaques infected with H5N1
HPAIVs. In the macaque that died on day 5 (Ho3), hemorrhage
and lymphocyte infiltration in alveolar spaces were observed
(Figure 2C). Formation of hyaline membranes was observed in
part, suggesting that diffuse alveolar damage and acute respiratory
distress syndrome occurred (Figure 2F). In each macaque,
influenza A virus antigen (green) was detected by immunofluores-
cence staining mainly in the nuclei (bright green after merging)
and partially in the cytoplasm (yellow after merging) of type II
pneumocytes that were cuboidal alveolar lining cells positive for
pan-cytokeratin (red) (Figure 2G–I). The distribution of viral
antigen-positive cells was focal and patchy in the lungs of the
macaques infected with VN3040, whereas the distribution was
diffuse in the lungs of macaques infected with HOK1 (Figure 2J,
K). Especially in Ho3, viral antigen-positive cells were observed in
every alveolus, which correlated with the severity of pneumonia
(Figure 2L). Although HOK1 showed higher pathogenicity in
cynomolgus macaques than did VN3040, both H5N1 HPAIVs
used in the present study induced severe morbidity with viral
pneumonia in cynomolgus macaques and that they were
considered suitable for evaluation of vaccine efficacy.
Antibody Responses in Macaques after Vaccination with
Vac-3
To examine the immunogenicity of Vac-3 in macaques, we
inoculated twelve macaques with inactivated whole viral particles
of Vac-3 subcutaneously twice with a two-week interval without
addition of an adjuvant since inactivated whole virus particles
included viral RNA as an internal adjuvant and the interval was
sufficient to prime and boost immune responses within a month
from initiation of vaccination in our previous studies using
macaques [12,13,16]. Two weeks after the first vaccination (before
the second vaccination), IgG antibody specific for Vac-3 antigen
was detected in plasma, nasal swab samples, and tracheal swab
samples from all vaccinated macaques (Figure S2A–C). Two weeks
after the second vaccination (four weeks after the first vaccination),
levels of IgG specific for Vac-3 antigen were increased in all
macaques. No production of IgA specific for Vac-3 antigen was
detected in plasma (Figure S2D). On the other hand, IgA
production was detected in nasal swab samples from all macaques
except NL4 and in tracheal samples from only one macaque, NL5
(Figure S2E, F). Plasma collected from all vaccinated macaques 2
weeks after the second vaccination (week 4) showed neutralization
activity against the vaccine strain, Vac-3 (Table 3). Thus, the
whole particle vaccine of Vac-3 was immunogenic in cynomolgus
macaques.
Challenge Infection of Macaques Immunized with Vac-3
To examine the efficacy of vaccination with Vac-3, challenge
virus strains VN3040 and HOK1, which have similarity of amino
acid sequences to Vac-3 between 89% and 93% in HA and NA
(Table S3), were inoculated into the vaccinated macaques. All
macaques infected with VN3040 and two macaques infected with
HOK1 (Ho4 and Ho5) showed higher body temperatures after
infection than those before virus infection (Figure 3). The other
macaque infected with HOK1 (Ho6) showed a rise in body
temperature at night. The high body temperatures returned to
normal levels on day 3 after infection and all of the macaques
survived until day 7, at which point the study was terminated for
tissue collection. Clinical scores of the vaccinated macaques
infected with HOK1 were significantly lower than those of
unvaccinated macaques 2 to 5 days after virus infection (Figure
A Vaccine Effective for H5N1 Influenza Infection
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S1B). Virus was detected in oral samples from the macaques
inoculated with VN3040 until day 5 and in nasal, oral, and
tracheal samples from macaques inoculated with HOK1 until day
2 after infection (Tables 1 and 2). The durations of virus detection
in the vaccinated macaques were shorter than those in the
unvaccinated macaques. Virus titer areas under the virus titer time
curves (virus titer AUCs) in the samples from vaccinated macaques
were significantly lower than those in samples from unvaccinated
macaques (Figure S1E, F). No virus was detected in tissue samples
obtained at autopsy on day 7 after infection (data not shown).
Therefore, vaccination with whole viral particles of Vac-3
inhibited H5N1 HPAIV propagation in macaques and reduced
morbidity.
Next, a different subtype of HPAIV, A/chicken/Netherlands/
2586/2003 (H7N7) (NL2586), or a pandemic (H1N1) 2009 virus,
A/Narita/1/2009 (H1N1) (NRT1), was inoculated into macaques
vaccinated with Vac-3 to examine crossreactivity of immunity
induced by Vac-3. As for the unvaccinated macaques infected with
NL2586 or NRT1, some data reported previously were cited for
the comparison with the vaccinated macaques [16,17]. The
vaccinated macaques showed higher body temperatures after
infection with NL2586 than those before infection (Figure S3,
upper right), as seen in the unvaccinated macaques in the previous
study (Figure S3, upper left) [16]. No significant improvement in
the clinical scores of the vaccinated macaques was seen compared
with the unvaccinated macaques (Figure S1C). One of the
macaques (NL5) vaccinated with Vac-3 died on day 4 after
NL2586 virus infection. Virus in nasal, oral, tracheal, and
bronchial samples from the vaccinated macaques was detected
until day 6, day 5, day 7 and day 4 after virus infection,
respectively (Table 4). On the other hand, in the unvaccinated
macaques, of which virus titers in nasal samples were previously
reported [16], virus in nasal, oral, tracheal, and bronchial samples
was detected until day 6, day 7, day 7 and day 6, respectively. No
significant differences in the virus titer AUCs of the vaccinated and
unvaccinated macaques until day 4 were seen (Figure S1G).
Therefore, vaccination with Vac-3 had little effect on protection
against H7N7 virus infection, though durations of virus detection
in oral and bronchial samples from the vaccinated macaques were
two days shorter than those of virus detection in oral and bronchial
samples from the unvaccinated macaques.
In the vaccinated macaques infected with NRT1, although
clinical scores were not significantly different between vaccinated
and unvaccinated macaques (Figure S1D), increase in body
temperature was not as great as increases in body temperatures
of macaques infected with HPAIVs and unvaccinated macaques
previously reported (Figure S3, lower graphs) [17]. A low level of
virus was detected in samples from one macaque (NR4) compared
with virus in unvaccinated macaques previously reported [17]
(Table 5). No virus was detected in samples from two other
macaques (NR5 and NR6). Therefore, virus titer AUCs of the
vaccinated macaques were significantly lower than those of the
unvaccinated macaques (Figure S1H). Thus, vaccination with
Vac-3 induced protective immunity against the pandemic (H1N1)
2009 virus NRT1.
Figure 1. Body temperature of cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus. Highly pathogenic
avian influenza virus A/Vietnam/UT3040/2004 (H5N1) (left, VN3040) or A/whooper swan/Hokkaido/1/2008 (H5N1) (right, HOK1) was inoculated into
the nostrils, oral cavity, and trachea of each macaque on day 0. Body temperature of macaques was recorded using telemetry transmitters and a
computer. Temperatures from 6 P.M. to 10 A.M. are shown in the graphs since temperatures between 10 A.M. and 6 P.M. were affected by
anesthesia.
doi:10.1371/journal.pone.0082740.g001
A Vaccine Effective for H5N1 Influenza Infection
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Antibody Responses after Challenge Infection in
Macaques Immunized with Vac-3
Immune responses after challenge infection were determined to
examine the contribution to protection by humoral and cellular
immunity, especially immunity against H1N1 virus, since vacci-
nation with Vac-3 inhibited virus propagation in macaques
infected with heterosubtypic NRT1. Neutralization activity against
Vac-3 in plasma of macaques infected with VN3040 or HOK1
was increased one to five days after challenge infection (Table 3).
The vaccinated macaques challenged by H5N1 HPAIVs showed
increase in neutralization activity in plasma against VN3040 or
HOK1 five to seven days after challenge infection, though no
neutralization activity against challenge viruses was detected
before infection (Table 6). The responses seen in the vaccinated
macaques were recall memory responses generated by vaccination
and reactivated by challenge infection since no neutralization
activity against VN3040 or HOK1 was detected in plasma
collected on day 7 after infection from the unvaccinated macaques
(Table 6).
No neutralization activity against NL2586 or NRT1 was
detected in plasma collected 7 days after challenge infection in
the unvaccinated and vaccinated macaques (Table 6). Further-
more, no increase in neutralization activity against Vac-3 in
plasma was seen on day 7 after challenge infection (Table 3).
Therefore, memory neutralization antibody responses were not
reactivated by challenge infection with NL2586 or NRT1.
Furthermore, antibody induced by vaccination with Vac-3 did
not show crossreactivity against NL2586 since virus titers in
samples from the vaccinated macaques were not different from
those in samples from the unvaccinated macaques (Table 4).
We examined anti-NA antibody using neuraminidase inhibition
(NI) assay since anti-HA antibody was mainly detected by the
neutralization test [18]. Vaccination with Vac-3 induced NI
activity against NA of Vac-3 in plasma of the vaccinated macaques
two weeks after the second vaccination (Table 7). The same
samples also showed NI activity against NA of NRT1. Seven days
after challenge infection with NRT1, macaques without vaccina-
tion showed low NI titers against NRT1 but not against Vac-3 in
plasma. On the other hand, plasma of two macaques vaccinated
with Vac-3 (NR4 and NR5) on day 7 showed NI activity against
Vac-3 and NRT1 with higher titers than that of the macaques
before challenge infection (day 0). These results indicated that
anti-NA antibody induced by the Vac-3 vaccine reacted with NA
of NRT1 and that the antibody responses were reactivated by
challenge infection with NRT1 as memory recall responses.
Table 1. Virus titers in swab samples from cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus,
VN3040.
Virus titers (log10TCID50/ml)
Days after infection
Sample Vaccine Animal 1 2 3 4 5 6 7
Nasal cavity 2 VN1 2.45 2.45 1.75 2.56 1.40 ,* ,
2 VN2 5.36 3.84 2.80 3.84 3.26 3.15 2.95
2 VN3 , 2.10 1.63 4.66 5.21 5.39 3.84
+ VN4 2.00 , , , , , ,
+ VN5 2.50 1.77 1.50 1.23 , , ,
+ VN6 , , , , , , ,
Oral cavity 2 VN1 , 3.15 2.33 , , 1.92 ,
2 VN2 3.03 2.10 1.63 1.86 1.94 ,* ,
2 VN3 , 2.10 2.68 2.56 2.56 2.80 ,
+ VN4 2.50 , , , , , ,
+ VN5 2.77 2.00 , , 1.83 , ,
+ VN6 , , , , , , ,
Trachea 2 VN1 5.21 5.77 3.84 2.80 3.66 4.03 2.21
2 VN2 3.84 2.56 1.75 , 2.26 1.63 ,
2 VN3 4.43 3.84 3.26 3.66 3.03 3.15 ,
+ VN4 2.33 , , , , , ,
+ VN5 1.50 1.50 , 2.33 , , ,
+ VN6 ,* , , , , , ,
Bronchus 2 VN1 5.13 3.84 4.43 3.38 4.51 3.03 3.96
2 VN2 3.84 2.10 2.63 , , , ,
2 VN3 4.19 3.15 3.66 2.10 1.56 ,* ,
+ VN4 2.23 ,* , , , , ,
+ VN5 2.50 1.33 , , , , ,
+ VN6 , , , , , , ,
,: Virus titers were under the detection limit (0.67 TCID50/ml).
,*: One CPE positive well was observed in quadruplicate culture of undiluted samples.
doi:10.1371/journal.pone.0082740.t001
A Vaccine Effective for H5N1 Influenza Infection
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T lymphocyte Responses after Challenge Infection in
Macaques Immunized with Vac-3
To examine T cell responses in vaccinated macaques, we
cultured cervical lymph node cells with autologous B cell lines
infected with challenge virus as antigen-presenting cells (APC)
since cervical lymph nodes were larger and easier to detect than
mediastinal lymph nodes at autopsy. Although interferon (IFN)-c
production by lymphocytes was detected in the supernatant
cultured with B cell lines without virus infection (Figure 4A), IFN-c
production by lymphocytes obtained from the vaccinated
macaques except Ho4 and Ho5 was significantly up-regulated in
the presence of APC infected with challenge virus (P,0.05). These
results indicated that macaques vaccinated with Vac-3 carried
lymphocytes responding to challenge virus antigens on day 7 after
challenge infection.
Finally, we examined cells producing IFN-c in the vaccinated
macaques. Cervical lymph node cells were cultured with
autologous B cell lines with or without challenge virus infection
for 5 days to expand responding cells, and then the cells were
restimulated to determine the percentage of IFN-c-producing cells
[13]. Since we did not obtain a sufficient number of live lymph
node cells from culture with APC infected with H5N1 HPAIVs,
we analyzed cells from macaques infected with NRT1 (Figure 4B).
IFN-c-positive cells in CD8+ ((NR4 (12.6%), NR6 (10.5%)) and
CD4+ (NR4 (4.2%)) cells cultured with APC infected with NRT1
were detected more frequently than IFN-c- positive cells in CD8+
(NR4 (2.0%), NR6 (7.3%)) and CD4+ (NR4 (0.3%)) cells cultured
with uninfected APC. In NR5, the percentage of IFN-c-positive
cells in CD4+ and CD8+ cells did not increase after culture with
APC infected with NRT1. These results indicated that CD4+ and/
or CD8+ cells in two macaques vaccinated with Vac-3 were
reactive to NRT1-infected cells. Therefore, both humoral and
cellular immune responses against NRT1 were detected in
macaques vaccinated with Vac-3.
Discussion
Potency of Vac-3 vaccine was previously examined in chickens
using H5N1 HPAIVs [15]. In the present study, to evaluate
efficacy of the vaccine in a non-human primate model, we selected
challenge strains that propagated vigorously in macaques. Two
H5N1 HPAIVs, VN3040 (clade 1) and HOK1 (clade 2.3.2.1),
caused viral pneumonia in macaques without vaccination, to
degrees similar to that reported previously [19], and with more
severe morbidity than did another H5N1 HPAIV, A/Vietnam/
Table 2. Virus titers in swab samples from cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus,
HOK1.
Virus titers (log10TCID50/ml)
Days after infection
Sample Vaccine Animal 1 2 3 4 5 6 7
Nasal cavity 2 Ho1 1.50 ,1 , ,* ,1 2.00 ,1.3
2 Ho2 4.50 2.23 2.50 2.50 2.67 2.50 2.50
2 Ho3 3.70 , 3.67 2.33 3.50 NT NT
+ Ho4 , , , , , , ,
+ Ho5 , , , , , , ,
+ Ho6 , 1.33 , , , , ,
Oral cavity 2 Ho1 2.50 1.50 1.50 , , 1.33 2.50
2 Ho2 5.00 2.33 1.50 1.67 2.50 2.33 2.33
2 Ho3 2.00 , 2.00 3.33 1.33 NT NT
+ Ho4 , , , , , , ,
+ Ho5 , , , , , , ,
+ Ho6 , 1.67 , , , , ,
Trachea 2 Ho1 4.50 4.00 3.23 2.50 2.50 2.33 2.67
2 Ho2 5.67 3.67 2.33 4.00 3.33 3.50 2.67
2 Ho3 4.50 3.33 2.50 3.33 2.50 NT NT
+ Ho4 1.33 , , , , , ,
+ Ho5 1.50 , , , , , ,
+ Ho6 ,* 1.33 , , , , ,
Bronchus 2 Ho1 4.00 2.67 1.50 ,1 1.33 ,1 ,
2 Ho2 4.67 3.50 2.50 2.00 3.00 , 2.67
2 Ho3 4.33 2.67 1.50 1.50 2.67 NT NT
+ Ho4 1.50 , , , , , ,
+ Ho5 3.50 , , , , , ,
+ Ho6 3.00 , , , , , ,
,: Virus titers were under the detection limit (0.67 TCID50/ml).
,*: One CPE positive well was observed in quadruplicate culture of undiluted samples. NT: not tested.
doi:10.1371/journal.pone.0082740.t002
A Vaccine Effective for H5N1 Influenza Infection
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1194/2004 (clade 1) [11]. Subcutaneous vaccination with inacti-
vated whole particles of Vac-3 induced anti-HA neutralization
antibody against H5N1 HPAIVs after challenge infection and
anti-NA antibody with neuraminidase inhibition activity against
Vac-3 and pandemic (H1N1) 2009 virus. Vaccination with Vac-3
also activated T cells producing IFN-c in lymph nodes of
macaques. In challenge infection, virus propagation was signifi-
cantly inhibited in macaques infected with either H5N1 HPAIVs
or H1N1 pandemic virus but not in macaques infected with H7N7
HPAIV even when only three macaques (the minimal number for
statistics) were used in each group to reduce the number of animals
in the study. Therefore, the whole particle vaccine of Vac-3 was
effective for preventing propagation of two different clades of
H5N1 HPAIVs and a different subtypic H1N1 virus.
Cross-clade immune responses induced by H5N1 influenza
vaccines have been reported in mice [9,20,21] and ferrets [22,23].
In a nonhuman primate model, cross-clade neutralizing antibodies
induced by an H5N1 influenza vaccine were reported [24], but
protective immunity against challenge infection has not been
assessed. In humans, results of a clinical trial of a whole particle
H5N1 vaccine were reported [25], and cellular responses were
evaluated [26]. However, the efficacy of vaccines against challenge
infection was unknown due to difficulty in performing challenge
infection in humans. Furthermore, according to epidermiologic
behavior of influenza viruses in humans, it was believed that
natural infection and current vaccination with split vaccines
induced only weak cross-reactive immunity in humans [27,28].
Thus, we evaluated the crossreactivity of immune responses
induced by a whole particle H5N1 vaccine in a non-human
primate model, in which immunological responses are presumably
the closest to those in humans among available experimental
animals.
Seven days after challenge infection with H5N1 HPAIVs, all
macaques vaccinated with Vac-3 showed neutralization activity in
plasma, but neutralization antibody against H5N1 viruses was not
detected in plasma of the unvaccinated macaques. Therefore, it
was thought that the neutralization activity against challenge
viruses was induced by vaccination. Furthermore, neutralization
activity against Vac-3 on day 7 after infection was higher than that
against Vac-3 on day 0. This means that challenge infection with
Figure 2. Viral pneumonia in macaques infected with H5N1 highly pathogenic avian influenza virus. One macaque, VN1 (A, D, G, J), was
inoculated with VN3040. Two macaques, Ho2 (B, E, H, K) and Ho3 (C, F, I, L), were inoculated with HOK1. VN1 and Ho2 were autopsied 7 days after
virus inoculation. The dead macaque Ho3 was autopsied 5 days after virus infection. (A–F) Lung tissue sections were stained with H & E. A–C: low
magnification (bars: 200 mm), D–F: high magnification (bars: 50 mm). (G–I) Viral antigen was stained with FITC-conjugated anti-influenza A virus
antibody (green) in combination with eFluor615-conjugated cytokeratin (red) and DAPI for staining of nuclei (blue). (J–L) The distribution of viral
antigen in lungs stained with FITC-conjugated anti-influenza A virus antibody (bright green). The images were analyzed under a sobel edge detection
filter.
doi:10.1371/journal.pone.0082740.g002
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H5N1 HPAIVs activated B cells specific for Vac-3. Since
neutralization activity against challenge strains was not detected
before challenge infection, neutralization antibody induced by
Vac-3 mainly reacted with Vac-3 before infection, but challenge
infection activated B cells producing antibodies reacting with both
Vac-3 and H5N1 HPAIV challenge strains. Therefore, the Vac-3
vaccine would elicit antibodies against common antigenic epitopes
shared among Vac-3, clade 1, and clade 2.3.2.1 H5N1 viruses.
Inhibition of virus propagation was also observed in the
vaccinated macaques infected with NRT1. Since no neutralization
activity against NRT1 was detected in plasma of the vaccinated
macaques before and after challenge infection with NRT1,
Table 3. Neutralization activity against the vaccine strain Vac-3 in plasma.
Weeks after 1st vaccination Days after challenge infection
Challenge Animal 0 2 4 0 1 3 5 7
VN3040 VN4 ,2 4.7 7.2 5.9 5.6 6.5 7.0 8.1
VN5 ,2 2.6 4.4 5.6 7.5 7.1 6.9 10.1
VN6 ,2 4.6 7.5 7.6 10.0 9.6 11.1 .12
HOK1 Ho4 ,4 ,2 5.5 6.9 8.5 9.3 10.4 11.4
Ho5 ,2 2.3 9.1 7.9 9.1 5.3 9.0 8.8
Ho6 ,2 2.6 5.8 5.6 4.8 5.5 6.3 8.8
NL2586 NL4 ,2 ,2 3.8 4.5 4.6 4.8 4.6 4.6
NL5 ,2 7.9 10.8 11.4 11.6 10.9 8.8 NT
NL6 ,2 6.2 11.1 8.7 5.9 9.1 9.6 9.6
NRT1 NR4 ,2 ,2 4.6 7.9 5.7 6.1 6.3 6.3
NR5 ,2 3.1 8.0 7.8 6.6 6.9 5.0 5.2
NR6 ,2 2.7 6.9 9.0 9.1 9.1 8.8 9.1
Dilution titers that show 50% neutralization activity are indicated as log2 dilution. NT: not tested. The interval between 4 weeks after the first vaccination and day 0 (day
of infection) was 3 weeks.
doi:10.1371/journal.pone.0082740.t003
Figure 3. Body temperature of vaccinated macaques infected with H5N1 highly pathogenic avian influenza virus. H5N1 highly
pathogenic avian influenza virus VN3040 (left) or HOK1 (right) was inoculated into the nostrils, oral cavity, and trachea of macaques on day 0 (five
weeks after the second vaccination). Body temperatures of macaques were recorded using telemetry transmitters and a computer. Temperatures
from 6 P.M. to 10 A.M. are shown in the graphs since temperatures between 10 A.M. and 6 P.M. were affected by anesthesia.
doi:10.1371/journal.pone.0082740.g003
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immunity other than antibodies against HA would contribute to
protection against NRT1 infection. NI activity against Vac-3 and
NRT1 was detected in plasma of the vaccinated macaques, and
the NI activity in two macaques (NR4 and NR5) was increased
after challenge infection. In addition, IFN-c-producing CD4+ and
CD8+ T cells specific for NRT1 antigens were detected in two
vaccinated macaques (NR4 and NR6). Therefore, it was thought
that both antibodies against NA and T cells specific for antigens
shared in Vac-3 and NRT1 contributed to protection against
NRT1 infection in the vaccinated macaques.
The extent of contribution of anti-NA antibodies and T cells to
protective immunity in previous studies varied [29–32] and was
dependent on individual macaques in the present study. In NR4,
both anti-NA antibodies and T cells specific for NRT1 antigens
seemed to have worked for inhibition of virus propagation since
both NI activity and IFN-c-producing CD8+/CD4+ T cells against
NRT1 were increased after challenge infection. In NR5, anti-NA
antibodies might have mainly worked for inhibition of virus
propagation rather than T cells since NI activity in plasma was
increased after infection, but IFN-c responses against NRT1 by
CD4+ and CD8+ T cells were not detected. On the other hand, in
NR6, CD8+ T cells might have mainly worked for protection since
IFN-c-producing CD8+ T cells but not CD4+ T cells against
NRT1 were detected without an increase in NI activity after
infection. Although CD8+ T cells were thought to be important to
eliminate influenza viruses in mice [33] and preexisting influenza-
specific CD4+ T cells correlated with disease severity in humans
[34], the role of T cells, either CD8+ or CD4+ T cells, in human
influenza virus infection remains elusive since both CD4+ and
CD8+ T cells were expanded 7 days after challenge infection [34].
In our nonhuman primate model of influenza virus infection, the
differential contribution of T cell subsets in individual macaques
suggests that genetic variations including major histocompatibility
complex haplotypes might affect immune responses in vaccination
and in infection [13].
Vaccination with Vac-3 did not show protection against H7N7
HPAIV infection in macaques. Vaccinated macaques infected
with H7N7 HPAIV showed severe morbidity, and virus titers in
swab samples from the vaccinated macaques were at similar levels
to those in swab samples from the unvaccinated macaques. No
neutralization activity in plasma against H7N7 was induced in
vaccinated macaques, but IFN-c production by T lymphocytes
against NL2586 was detected. These results suggested that
antibody responses with neutralization activity were more
important than T lymphocyte responses in protection against
HPAIV infection, though T lymphocyte responses against H5N1
Table 4. Virus titers in swab samples from cynomolgus macaques infected with NL2586.
Virus titers (log10 TCID50/ml)
Days after infection
Sample Vaccine Animal 1 2 3 4 5 6 7
Nasal cavity 2 NL1 3.50 3.67 3.00 5.33 3.50 2.67 ,
2 NL2 2.67 2.33 2.00 2.23 , ,* ,
2 NL3 ,* , ,* 1.67 1.67 2.50 ,
+ NL4 4.50 3.33 3.50 2.50 2.23 1.50 ,
+ NL5 4.67 3.67 2.50 2.23 NT NT NT
+ NL6 4.50 2.67 2.67 1.67 2.33 , ,
Oral cavity 2 NL1 2.33 1.67 1.50 ,* 2.33 ,* 1.50
2 NL2 2.00 2.33 ,* , , , ,*
2 NL3 2.67 ,* , , 2.00 2.50 ,*
+ NL4 4.67 3.00 2.17 1.67 , , ,
+ NL5 1.67 2.50 1.50 2.33 NT NT NT
+ NL6 4.33 , 1.23 ,* 1.67 , ,
Trachea 2 NL1 3.33 3.33 ,* 3.00 3.33 2.83 ,
2 NL2 4.23 2.00 ,* ,* ,* ,* ,*
2 NL3 2.67 1.67 , ,* 2.00 3.00 ,
+ NL4 4.50 3.77 1.33 2.00 2.50 2.33 ,*
+ NL5 3.50 3.23 1.50 2.33 NT NT NT
+ NL6 5.33 2.67 1.83 , 0.83 , ,
Bronchus 2 NL1 3.50 3.67 2.50 1.67 4.33 1.50 ,
2 NL2 3.67 2.50 1.50 ,* ,* , ,
2 NL3 3.50 3.67 1.50 , 2.67 , ,
+ NL4 3.67 3.77 , , , , ,
+ NL5 3.67 2.67 , 1.33 NT NT NT
+ NL6 4.50 3.23 , , , , ,
,: Virus titers were under the detection limit (0.67 TCID50/ml).
,*: One CPE positive well was observed in quadruplicate culture of undiluted samples. NT: not tested. Virus titers in nasal samples from unvaccinated macaques were
referred from a reference 16.
doi:10.1371/journal.pone.0082740.t004
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HPAIVs might have helped the elimination of VN3040 and
HOK1 viruses in vaccinated macaques [35].
In summary, we demonstrated that a whole particle vaccine
of Vac-3 induced protective immune responses against two
clades of H5N1 HPAIVs and a pandemic (H1N1) 2009 strain
in cynomolgus macaques. We found that neutralization activity
induced by vaccination was crucial for protection from HPAIVs
and that antibody responses with neuraminidase inhibition
activity and T lymphocyte responses might be sufficient to
protect against non-HPAIV virus infection. In our previous
study on a comparison of the efficacy of a whole particle
vaccine and that of an ether-split vaccine against pandemic
(H1N1) 2009 virus infection [13], protective efficacy of the
ether-split vaccine was less potent than that of the whole
particle vaccine even when the subtype of the vaccine was the
same as that of the challenge strain. Therefore, whole particle
vaccines are preferable to induce immunity not only for
homosubtypic protection but also for cross-clade and hetero-
subtypic protection.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
Guidelines for the Husbandry and Management of Laboratory
Animals of the Research Center for Animal Life Science at
Shiga University of Medical Science and Standards Relating to
the Care and Management, etc. of Experimental Animals
(Notification No.6, March 27, 1980 of the Prime Minister’s
Office, Japan). The protocols were approved by the Shiga
University of Medical Science Animal Experiment Committee
(Permit numbers: 2008-5-11, 2009-8-6H, 2010-10-1, 2011-4-2H,
and 2012-10-8). The animal experiments were conducted in
strict compliance with animal husbandry and welfare regula-
tions. The Research Center for Animal Life Science at the
Shiga University of Medical Science has a permit for
importation of cynomolgus macaques. Regular veterinary care
and monitoring, balanced nutrition and environmental enrich-
ment were provided by the Research Center for Animal Life
Science at the Shiga University of Medical Science. The
macaques were euthanized at endpoint (7 days after virus
inoculation) using ketamine/xylazine followed by intravenous
injection of pentobarbital (200 mg/kg). Animals were monitored
Table 5. Virus titers in swab samples from cynomolgus macaques infected with NRT1.
Virus titers (log10TCID50/ml)
Days after infection
Sample Vaccine Animal 1 2 3 4 5 6 7
Nasal cavity 2 NR1 , 3.49 3.15 5.21 4.69 3.15 ,
2 NR2 , 3.03 2.80 2.21 5.94 4.51 2.26
2 NR3 4.54 4.51 5.36 5.36 4.66 3.84 ,
+ NR4 1.23 , , , , , ,
+ NR5 , , , , , , ,
+ NR6 , , , , , , ,
Oral cavity 2 NR1 , , , 2.56 3.03 , ,
2 NR2 , , , 2.45 , 1.75 ,
2 NR3 3.49 , , , 1.63 3.26 ,
+ NR4 , , , , , , ,
+ NR5 , , , , , , ,
+ NR6 , , , , , , ,
Trachea 2 NR1 , , , 3.84 4.51 3.96 ,
2 NR2 , , , 1.94 1.56 2.80 3.13
2 NR3 3.84 3.49 3.96 4.19 5.59 3.84 ,
+ NR4 , , , , , , ,
+ NR5 , , , , , , ,
+ NR6 , , , , , , ,
Bronchus 2 NR1 , , , 3.03 5.05 4.03 ,
2 NR2 , , , ,* ,* 2.80 ,
2 NR3 2.40 ,* 1.40 , 1.40 , 2.10
+ NR4 , , 1.23 , , , ,
+ NR5 , , , , , , ,
+ NR6 , , , , , , ,
,: Virus titers were under the detection limit (0.67 TCID50/ml).
,*: One CPE positive well was observed in quadruplicate culture of undiluted samples. Virus titers in nasal, tracheal, and bronchial samples from unvaccinated
macaques were referred from a reference 17.
doi:10.1371/journal.pone.0082740.t005
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every day during the study to be clinically scored as shown in
Table S4 [19] and to undergo veterinary examinations to help
alleviate suffering. Animals would be euthanized if their clinical
scores reached 15 (a humane endpoint).
Table 6. Neutralization activity against challenge strains in plasma of macaques.
Weeks after 1st vaccination Days after infection
Challenge virus Vaccine Animal 2 4 0 5 7
VN3040 2 VN1 NT NT ,2 NT ,2
2 VN2 NT NT ,2 NT ,2
2 VN3 NT NT ,2 NT ,2
+ VN4 ,2 ,2 ,2 ,2 4.0
+ VN5 ,2 ,2 ,2 ,2 3.3
+ VN6 ,2 ,2 ,2 2.7 6.0
HOK1 2 Ho1 NT NT ,2 NT ,2
2 Ho2 NT NT ,2 NT ,2
2 Ho3 NT NT ,2 NT ,2
+ Ho4 ,2 ,2 ,2 ,2 4.0
+ Ho5 ,2 2.0 ,2 2.3 5.5
+ Ho6 ,2 ,2 ,2 ,2 3.7
NL2586 2 NL1 NT NT ,2 ,2 ,2
2 NL2 NT NT ,2 ,2 ,2
2 NL3 NT NT ,2 ,2 ,2
+ NL4 ,2 ,2 ,2 ,2 ,2
+ NL5 ,2 ,2 ,2 ,2 NT
+ NL6 ,2 ,2 ,2 ,2 ,2
NRT1 2 NR1 NT NT ,2 NT ,2
2 NR2 NT NT ,2 NT ,2
2 NR3 NT NT ,2 NT ,2
+ NR4 ,2 ,2 ,2 ,2 ,2
+ NR5 ,2 ,2 ,2 ,2 ,2
+ NR6 ,2 ,2 ,2 ,2 ,2
50% neutralization titers are indicated as log2 dilution. NT: not tested. The interval between 4 weeks after the first vaccination and day 0 (day of infection) was 3 weeks.
doi:10.1371/journal.pone.0082740.t006
Table 7. Neuraminidase inhibition activity against Vac-3 and NRT1 in plasma of macaques infected with NRT1.
Weeks after 1st vaccination Days after challenge infection
NA source Vaccine Animal 0 4 0 7
Vac-3 2 NR1 NT NT , ,
2 NR2 NT NT , ,
2 NR3 NT NT , ,
+ NR4 , 16 16 64
+ NR5 , 16 16 16
+ NR6 , 4 16 16
NRT1 2 NR1 NT NT , 1
2 NR2 NT NT , 4
2 NR3 NT NT , 4
+ NR4 , 4 4 64
+ NR5 , 4 1 64
+ NR6 , 4 16 16
,: NI activity was under the detection limit (1 = undiluted samples). NT: not tested.
doi:10.1371/journal.pone.0082740.t007
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Animals
Five- to eight-year-old female cynomolgus macaques from
Vietnam and the Philippines were used. The cynomolgus
macaques used in the present study were healthy adults. All
procedures were performed under ketamine and xylazine anes-
thesia, and all efforts were made to minimize suffering. Food
pellets of CMK-2 (CLEA Japan, Inc., Tokyo, Japan) were
provided once a day after recovery from anesthesia and drinking
water was available ad libitum. Animals were singly housed in the
cages equipping bars to climb up and puzzle feeders for
environmental enrichment under controlled conditions of humid-
ity (26–64%), temperature (24–26uC), and light (12-h light/12-h
dark cycle, lights on at 8:00 A.M.). In the text and figures,
individual macaques are distinguished by identification numbers
(Table S1). The absence of influenza A virus NP-specific
antibodies in their plasma was confirmed before experiments
using an antigen-specific enzyme-linked immunosorbent assay
(ELISA), AniGen AIV Ab ELISA (Animal Genetics Inc., Kyonggi-
do, Korea), for currently circulating influenza virus. Two weeks
before virus inoculation, a telemetry probe (TA10CTA-D70, Data
Sciences International, St. Paul, MN) was implanted in the
peritoneal cavity of each macaque under ketamine/xylazine
anesthesia followed by isoflurane inhalation to monitor body
temperature. The macaques used in this study were free from
herpes B virus, hepatitis E virus, Mycobacterium tuberculosis, Shigella
spp., Salmonella spp., and Entamoeba histolytica.
Under ketamine/xylazine anesthesia, two cotton sticks
(TE8201, Eiken Chemical, Ltd., Tokyo, Japan) were used to
collect fluid samples in nasal cavities, oral cavities, and tracheas,
and the sticks were subsequently immersed in 1 ml of PBS
containing 0.1% bovine serum albumin (BSA) and antibiotics. A
bronchoscope (MEV-2560, Machida Endoscope Co. Ltd., Tokyo,
Japan) and cytology brushes (BC-203D-2006, Olympus Corpora-
tion, Tokyo, Japan) were used to obtain bronchial samples [36].
Figure 4. T lymphocyte responses against B cell lines infected with challenge virus. (A) Cervical lymph node cells of vaccinated macaques
were isolated 7 or 4 days after challenge infection. The cells were cultured with autologous B cell lines as antigen-presenting cells (APC) with or
without challenge virus infection. Two days later, culture supernatants were collected and concentrations of IFN-c were measured using a bead array
assay. Averages and standard deviations of triplicate cultures are shown. Significant differences between APC and APC infected with challenge virus
(P,0.05, Student’s t-test) were detected except for Ho4 and Ho5. (B) Cervical lymph node cells from macaques infected with NRT1 were cultured with
autologous B cell lines with or without NRT1 infection in the presence of IL-2. Five days later, surviving cells were stimulated with PMA and ionomycin
for 5 h. Surface CD8 and CD4 and intracellular IFN-c were stained and analyzed using a flow cytometer. The percentages of IFN-c-positive cells in
CD4+ and CD8+ cells are indicated.
doi:10.1371/journal.pone.0082740.g004
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Viruses and Vaccines
We used the influenza virus A/duck/Hokkaido/Vac-3/2007
(H5N1) (Vac-3, National Center for Biotechnology Information
(NCBI) taxonomy database ID: 463698) as a vaccine strain [15].
This virus is a reassortant virus between A/duck/Hokkaido/101/
2004 (H5N3) and A/duck/Hokkaido/262/2004 (H6N1) [14].
The Vac-3 virus was propagated in allantoic cavities of 10-day-
old embryonated hen’s eggs at 35uC for 48 h. To prepare an
inactivated whole particle vaccine, the allantoic fluid infected with
Vac-3 was concentrated and purified by high-speed centrifugation
(112,500 g for 90 min) through a 10–50% sucrose density gradient
and then treated in 0.2% formalin at 4uC for one week [15].
Inactivation of viruses in the vaccine was confirmed by the absence
of detectable hemagglutination activity following inoculation of the
materials into embryonated eggs after one passage. The amount of
the whole particle vaccine is indicated as the amount of entire
proteins including HA and other viral proteins. The whole particle
vaccine (1 mg/dose) was inoculated subcutaneously into macaques
using syringes twice with a two-week interval between injections
under ketamine/xylazine anesthesia.
The following virus strains were used as challenge strains: A/
Vietnam/UT3040/2004 (H5N1) (VN3040, NCBI taxonomy ID:
755291) isolated from a human patient [37,38], A/whooper swan/
Hokkaido/1/2008 (H5N1) (HOK1, NCBI taxonomy ID: 527168)
isolated from a dead swan [39], and A/chicken/Netherlands/
2586/2003 (H7N7) (NL2586, NCBI taxonomy ID: 533037, kindly
provided by Dr. I. Capua (L’Office International des E´pizooties
(OIE), Food and Agriculture Organization of the United Nations
(FAO), and National Reference Laboratory for Newcastle Disease
and Avian Influenza, Istituto Zooprofilattico Sperimentale delle
Venezie, Italy) [12,16]. These viruses were highly pathogenic
avian influenza viruses. A/Narita/1/2009 (H1N1) (NRT1, NCBI
taxonomy ID: 645520, kindly provided by Dr. Takato Odagiri,
National Institute of Infectious Disease (NIID), Japan) [40] was a
pandemic influenza virus. VN3040 was propagated twice in
Madin-Darby canine kidney (MDCK) cells at the University of
Tokyo. HOK1 and NL2586 were propagated twice in embryo-
nated eggs. NRT1 was propagated in embryonated eggs twice at
NIID and once in MDCK cells (the American Type Culture
Collection, Manassas, VA) at the Shiga University of Medical
Science [13].
The macaques were challenged with VN3040 (36106 PFU50/
7 ml), HOK1 (36106 PFU/7 ml), and NRT1 (36106 TCID50/
7 ml) inoculated into the nostrils (0.5 ml for each nostril), oral
cavity (0.5 ml on the surface of each tonsil), and trachea (5 ml)
with pipettes and catheters 5 weeks after the second vaccination
under ketamine/xylazine anesthesia [17]. NL2586 (46107
TCID50/2 ml) was inoculated into the nostrils (0.45 ml for each
nostril), conjunctiva (0.05 ml for the surface of each conjunctiva),
and trachea (1 ml) [16]. In the present study, inoculation of NRT1
and NL2586 in unvaccinated macaques was not performed, but
results were cited from the previous studies [16,17]. The identical
lots and titers of NRT1 and NL2586 as those used in the previous
studies were inoculated into vaccinated macaques in the present
study. The inoculation volumes of NRT1 and NL2586 in
vaccinated macaques were determined in accordance with the
volumes in unvaccinated macaques in the previous report [16,17].
Experiments using challenge virus were performed in the biosafety
level 3 facility of the Research Center for Animal Life Science,
Shiga University of Medical Science.
In order to assess virus replication, serial dilutions of swab
samples were inoculated onto confluent MDCK cells as described
previously [11]. Cytopathic effects were examined under a
microscope 72 h later.
Detection of Antibody Specific for Virus Antigen by ELISA
The antibody titers of plasma and swab samples against Vac-3
antigens were determined using ELISA [41]. Ninety-six-well plates
were coated with 50 ml of purified Vac-3 (20 mg/ml) disrupted
with 0.05 M Tris-HCl (pH 7.8) containing 0.5% Triton X-100
and 0.6 M KCl. Serially diluted samples were incubated overnight
in the coated plates. After washing five times, horseradish
peroxidase (HRP)–conjugated anti-monkey IgG antibodies (MP
Biomedicals, Inc./Cappel, Aurora, OH) (1:2000650 ml) and anti-
monkey IgA antibodies (Nordic Immunological Laboratories,
Tilburg, The Netherlands) (1:4000650 ml) were added and
incubated for 1 h at room temperature. HRP activity was assessed
using 3, 39, 5, 59-tetramethyl benzidine substrate (100 ml). The
reaction was stopped by the addition of 1 M hydrogen chloride
(100 ml). Optical density (OD) was measured at 450 nm and
620 nm. Results are shown after subtraction of OD at 620 nm
from OD at 450 nm.
Virus Neutralization Assay
Plasma samples were pretreated with a receptor-destroying
enzyme (RDEII, Denka Seiken, Tokyo, Japan) at 37uC overnight
and then inactivated at 56uC for 1 h. The diluted samples were
mixed with 50 TCID50 of the VN3040, HOK1, NL2586, or
NRT1 viruses for 1 h. Then the mixture was added onto an
MDCK monolayer. After 1-h incubation, the cells were cultured
in Eagle’s minimal essential medium (MEM) containing 0.1%
BSA. For virus propagation of NRT1, 5 mg/ml trypsin was added
to the medium. After incubation at 35uC for 3 days, the number of
wells with cytopathic effects was counted in quadruplicate culture.
Neutralization titers were expressed as the dilution in which
cytopathic effects were observed in 50% of the wells.
For neutralization of Vac-3, 200 PFU of Vac-3 were mixed with
the diluted samples for 1 h. Then the mixture was added onto the
MDCK monolayer in 6-well plates. After 1 h, MDCK cells were
covered by MEM containing 1% agar, 0.1% BSA, and 5 mg/ml
trypsin. After incubation at 35uC for 2 days, the number of
plaques was counted. Neutralization titers were expressed as the
dilution in which the numbers of plaques were reduced to 50% of
plaques without plasma.
Neuraminidase Inhibition Test
Diluted plasma (25 ml) was incubated at room temperature for
1 h with Vac-3 or NRT1 virus. The dilution of the virus that was
used in the assays was standardized to the amount of NA activity
providing 0.5 OD at 549 nm in the thiobarbituric acid (TBA)
assay. Fetuin (50 ml, 25 mg/ml in 3 mM CaCl2N6H2O, 80 mM
Na2HPO4, 300 mM NaH2PO4, pH 5.9) was added and incubated
for 16 h at 37uC. NaIO4 (50 ml, 4.28 g in phosphate 62 ml+H2O
38 ml) was mixed for 20 min at room temperature. NaAsO2
solution (0.5 ml, 10 g NaAsO2 and 7.1 g Na2SO4 in 100 ml
H2O+0.3 ml H2SO4) was added and mixed with a vortex. TBA
solution (1.25 ml, TBA 6 mg/ml+Na2SO4 71 mg/ml) was added
to samples, boiled for 15 min, and then cooled on ice. N-butanol
(1.5 ml) was added, mixed with a vortex, and spun down for
10 min at 4000 rpm. ODs at 549 nm of upper layers were
measured. The NI titers were determined as the reciprocal of the
highest dilution of plasma that caused 50% inhibition of NA
activity.
B Cell Lines
Blood cells were obtained before the first vaccination.
Lymphocytes were purified from peripheral blood of the macaques
using a density gradient (Wako Pure Chemical Industries Ltd.,
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Osaka, Japan). After washing, cells were cultured in RPMI-1640
supplemented with 12% fetal calf serum (FCS) and supernatants of
TsB-B6 cells producing herpesvirus macaca fascicularis I (kindly
provided by Dr. Kazuhiko Hayashi, Tottori University, Japan)
[42,43]. More than 90% of the cells used in the present study were
positive for CD20.
Transformed B cells were washed twice with Hanks buffered
salt solution, and then influenza virus was added. After 30-min
incubation at 35uC, the cells were cultured in 5 ml of RPMI-1640
supplemented with 10% FCS and 2-mercaptoethanol (ME)
overnight. Mitomycin C (5 mg/ml) was added for the last
30 min. Cells were washed four times with Hanks buffered salt
solution and thereafter used as antigen-presenting cells.
Detection of IFN-c Production by Lymph Node Cells
Unfractionated cells (56105/well) from cervical lymph nodes
obtained at autopsy on day 4 or 7 after the challenge infection
were incubated with autologous B cell lines (2.56105/well) in the
presence of anti-CD28 (clone: CD28.2) and anti-CD49d (clone:
9F10) antibodies (0.5 mg/ml, eBioscience Inc., San Diego, CA) in
96-well U-bottom plates for 2 d. The concentration of IFN-c in the
supernatants was measured using Panomix Procarta Immunoas-
says for non-human primate cytokines (Affymetrix, Inc., Santa
Clara, CA) and Luminex200 (Millipore Corp., Billerica, MA).
Flow Cytometry for IFN-c Detection
Unfractionated cells (56105/well) from cervical lymph nodes
obtained at autopsy were incubated with autologous B cell lines
(2.56105/well) in the presence of anti-CD28, anti-CD49d
antibodies (0.5 mg/ml), and human IL-2 (10 ng/ml, Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) in 96-well U-
bottom plates for 5 d. The cultured lymph node cells were
stimulated with phorbol 12-myristate 13-acetate (PMA) (0.1 mg/
ml) and ionomycin (1 mg/ml) for 5 h. Monensin (2 mM) was added
for the last 4 h. Thereafter, cells were washed with PBS containing
EDTA (0.5 mM). Surface CD8 and CD4 were stained with
fluorescein isothiocyanate (FITC)- and allophycocyanin (APC)-
conjugated specific antibodies (clones: RPA-T8 and OKT-4,
eBioscience), respectively. Intracellular IFN-c was stained with
phycoerythrin (PE)-conjugated antibody (clone: 4S.B3,
eBioscience) after fixation with 4% paraformaldehyde and
permeabilization with 0.1% saponin. Dead cells were excluded
by staining with ethidium monoacetate (EMA, Molecular Probes,
Inc., Eugene, OR). IFN-c-positive cells were calculated as the
percentage in CD8- and CD4-positive cells [13].
Histopathological Examination and Detection of Viral
Antigen by Immunofluorescence Staining
For histopathological examination, lungs obtained at autopsy
were immersed in 10% neutral buffered formalin for fixation,
embedded in paraffin, and cut to 3 mm thick on glass slides.
Sections were stained with hematoxylin and eosin (H & E) and
observed under a light microscope. For immunofluorescence
staining, lung tissues were embedded in O.C.T. compound,
frozen, and cut to 5 mm thick on glass slides. After acetone
fixation, sections were incubated with 1% BSA in PBS for 30 min
and double stained with eFluor615-conjugated anti-pan-cytoker-
atin antibody (1:50 dilution, clone: AE1/AE3, eBioscience) and
FITC-conjugated goat polyclonal anti-influenza A virus antibody
(1:25 dilution, Abcam plc, Cambridge, United Kingdom) for 1 h
at room temperature. Nuclei were counterstained with 49, 6-
diamidino-2-phenylindole (DAPI). Then the tissues were observed
under a fluorescent microscope (FSX-100, Olympus Corporation).
The image data were analyzed with the cellSens Dimension
Desktop 1.5 software (Olympus Corporation).
Supporting Information
Figure S1 Clinical scores and total virus titers in
challenge infection. (A–D) Clinical scores were determined
by daily observation and body temperature, according to Table
S4. Averages and standard deviations of clinical scores are shown
in each group. (E–H) Virus titer areas under the virus titer time
curves (virus titer AUC) in nasal, oral, tracheal, and bronchial
samples were calculated on the basis of titers in Tables 1, 2, 4, and
5. Virus titers under the detection limit are calculated as 0.
Averages and standard deviations of three macaques are shown in
each group. Therefore, results of virus titers until day 7 (E and H),
day 5 (F), and day 4 (G) are used for calculation. A, E: macaques
infected with VN3040; B, F: macaques infected with HOK1; C,
G: macaques infected with NL2586; D, H: macaques infected with
NRT1. Red lines and bars: unvaccinated macaques, blue lines and
bars: vaccinated macaques. Asterisks indicate significant differ-
ences between unvaccinated groups and vaccinated groups
(P,0.05, Student’s t-test).
(TIF)
Figure S2 Antibody responses specific for Vac-3 anti-
gens in vaccinated cynomolgus macaques. Cynomolgus
macaques were subcutaneously immunized twice (in weeks 0 and
2) with a whole virus particle vaccine derived from Vac-3. Plasma
and swab samples were collected in indicated weeks after the first
vaccination. Lines indicate results of individual macaques. IgG (A–
C) and IgA (D–F) antibodies specific for Vac-3 antigens in plasma
(A, D), nasal swab samples (B, E), and tracheal swab samples (C, F)
were analyzed using ELISA. Optical densities at 450 nm at
indicated dilution are shown.
(TIF)
Figure S3 Body temperature of unvaccinated and
vaccinated macaques infected with H7N7 highly patho-
genic avian influenza virus or pandemic (H1N1) 2009
virus. H7N7 highly pathogenic avian influenza virus (NL2586)
(upper) or pandemic (H1N1) 2009 virus (NRT1) (lower) was
inoculated on day 0 (five weeks after the second vaccination)
(right). Body temperature of unvaccinated macaques was reana-
lyzed and cited from the previous studies for comparison (left)
[16,17]. Body temperatures of macaques were recorded using
telemetry transmitters and a computer. Temperatures from
6 P.M. to 10 A.M. are shown in the graphs since temperatures
between 10 A.M. and 6 P.M. were affected by anesthesia.
(TIF)
Table S1 Cynomolgus macaques used in the present
study. Abbreviations of challenge virus strains are used in the text
and figures. Unvaccinated (#1–#3) and vaccinated monkeys (#4–
#6) were used in this study.
(PDF)
Table S2 Virus titers in tissues obtained at autopsy.
Highly pathogenic avian influenza virus A/Vietnam/UT3040/
2004 (H5N1) (VN3040) or A/whooper swan/Hokkaido/1/2008
(H5N1) (HOK1) was inoculated into the nostrils, oral cavity, and
trachea of each macaque on day 0. VN1, VN2, VN3, Ho1, and
Ho2 were autopsied 7 days after virus inoculation. The dead
macaque Ho3 was autopsied 5 days after virus infection. Tissue
pieces of indicated organs were collected and virus titers in the
tissues were determined. ,: Virus titers under the detection limit
(,1.67 TCID50/g tissue). R: right, L: left, RU: right upper lobe,
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RM: right middle lobe, RL: right lower lobe, LU: left upper lobe,
LM: left middle lobe, LL: left lower lobe, LN: lymph nodes.
(PDF)
Table S3 Similarity of amino acid sequences in HA and
NA between Vac-3 and challenge strains. Amino acid
sequences of challenge strains are compared with that of a vaccine
strain, Vac-3. GI numbers of HA and NA were assigned by the
NCBI.
(PDF)
Table S4 Clinical scoring used in this study. Animals
were monitored every day during the study to be clinically scored.
Animals would be euthanized if their clinical scores reached 15 (a
humane endpoint).
(PDF)
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